In a report released on November 7, Jonathan Chang from Leerink Partners reiterated a Buy rating on Revolution Medicines (RVMD – Research ...

Revolution Medicines Inc's commitment to precision oncology positions it at the forefront of targeted cancer therapies.

Stifel Nicolaus analyst Benjamin Burnett maintained a Buy rating on Revolution Medicines (RVMD – Research Report) on November 8 and set a ...

Revolution Medicines (NASDAQ:RVMD – Free Report) had its target price increased by Needham & Company LLC from $61.00 to $68.00 in a report issued on Thursday morning,Benzinga reports. They currently ...

Revolution Medicines, Inc. (NASDAQ: RVMD) Q3 2024 Earnings Call Transcript November 6, 2024 Revolution Medicines, Inc. misses on earnings expectations. Reported EPS is $-0.94 EPS, expectations were ...

On Friday, Revolution Medicines Inc (RVMD) stock saw a modest uptick, ending the day at $60.44 which represents a slight increase of $1.34 or 2.27% from the prior close of $59.1. The stock opened at ...

Revolution Medicines Inc (RVMD) reports promising clinical progress and robust cash reserves, despite increased R&D and ...

The group was led by Casdin Capital, which surged 16 percent last month, according to an investor. This puts its share class that invests only in public securities up more than 40 percent for the year ...

As e-pharmacies race towards ultra-fast delivery, concerns mount over consumer safety, sustainability, and the future of ...

To celebrate Science Week and the theme of regeneration, we ask an expert in the field of cell therapy everything you might ...

In an economic dystopia, wealth concentrates at the top while intellectual and physical work are devalued. Widespread job ...